Introducing the pioneering AbiprotTM technology
We have a solid portfolio of promising future medicines and proprietary AbiprotTM technology, our evergreen antibody platform that can generate functional antibodies to any given disease-modifying target.
We are focusing on finding new treatment paradigms for severe diseases such as aggressive metastatic cancer and pain. We also work on two type 2 diabetes programs through a collaboration with big pharma.Learn more
Find out more about our portfolio
Oblique Therapeutics currently has eleven programs in the pipeline with a focus on pain and aggressive-metastatic cancer.
Four current programs are being developed in collaboration with leading pharmaceutical companies.Learn More